Background and Purpose-Hypertension is an important risk factor for cerebral small vessel disease. We aimed to study the effect of antihypertensive medication (AHM) on the progression of cerebral small vessel disease. Methods-We performed a systematic literature search of electronic databases up to January 30, 2017, for randomized controlled trials on the effect of AHM on ≥1 cerebral small vessel disease magnetic resonance imaging markers (ie, white matter hyperintensities, lacunes, microbleeds, enlarged perivascular spaces, acute small subcortical infarcts, and brain atrophy) after ≥1 year. We performed a random-effects meta-analysis using standardized mean difference. Results-We included 4 trials, including patients with stroke, with diabetes mellitus, and people ≥70 years of age. Patients in the AHM group had less progression of white matter hyperintensity during 28 to 47 months (standardized mean difference, −0.19; 95% confidence interval, −0.32 to −0.06; I 2 =20%; n=1369). Two trials reported on progression of brain atrophy with conflicting results. None of the trials reported on other cerebral small vessel disease markers. Conclusions-AHM has a protective effect on the progression of white matter hyperintensities, but no effect on brain atrophy. There are no trials on the effect of AHM on lacunes, microbleeds, enlarged perivascular spaces, or acute small subcortical infarcts. 
C erebral small vessel disease (SVD) is an aggregate term for damage to the small cerebral vessels characterized on neuroimaging by white matter hyperintensities (WMHs), lacunes, microbleeds, enlarged perivascular spaces, acute small subcortical infarcts, and brain atrophy. 1 With increasing severity, it is related to cognitive impairment and gait problems. 2 Hypertension is an important risk factor for cerebral SVD. 3 Although antihypertensive medication (AHM) is highly effective in preventing large-artery cerebrovascular disease and is well implemented in clinical practice, its effectiveness on SVD is yet unclear.
Our aim was to study the effect of AHM on progression of magnetic resonance imaging markers of cerebral SVD.
Methods
The protocol of this systematic review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards and registered on PROSPERO (CRD42017056873). All supporting data are available within the article and its online-only Data Supplement. We performed a systematic literature search up to January 30, 2017, in MEDLINE, EMBASE, the Cochrane Library, and BIOSIS. The search contained terms relating to AHM and cerebral SVD (Methods I in the online-only Data Supplement). We reviewed the reference list of selected articles for additional relevant studies. Two reviewers (T.v.M. and T.E.A.) screened and selected articles independent of one another, first based on title and abstract and then based on full text. We included randomized controlled trials studying the effect of AHM, during at least 1 year, on progression of at least 1 marker of cerebral SVD on magnetic resonance imaging. Risk of bias was assessed following the Cochrane Risk of Bias Tool. We contacted the authors of included trials in case data necessary for the meta-analysis were not available.
We pooled the individual cerebral SVD markers with a DerSimonian-Laird random-effects model. For continuous outcomes, we used a standardized mean difference according to Hedges' g effect size because the included trials used different methods to measure and report on SVD. We considered 3 trials the minimum for pooling results. We assessed statistical heterogeneity between the included studies using the I 2 statistic. We visually assessed the influence of difference in mean systolic blood pressure (BP) at follow-up between the intervention and control group. Please see Methods II in the online-only Data Supplement for additional information on statistical analyses. We used R studio package meta for the statistical analyses and plots.
Results
The literature search resulted in 2595 individual articles of which 4 individual trials could be included ( Figure 1 ). Risk of bias in the included studies was considered low or unclear (Table I in the online-only Data Supplement). Authors from 2 trials supplied additional data for the meta-analysis. 4, 5 The 4 trials included 1369 participants with average followup ranging from 28 to 47 months (Table) . Only 1 trial was not placebo controlled but compared a target systolic BP of ≤120 to ≤140 mm Hg. 6, 7 Two trials included patients with stroke, 5, 8 one included patients with diabetes mellitus, and one included individuals aged 70 to 89 years. 4 Cerebral SVD was a secondary outcome measure in all included trials. All 4 trials reported on WMH and 2 trials on brain atrophy as measured by automatic or manual measurement. None of the trials reported on lacunes, microbleeds, enlarged perivascular spaces, or acute small subcortical infarcts. One of the included trials did not report on total WMH volume, but because it did report volumetric measures of subcortical WMH, we included it in our meta-analysis (Table) . 5 In another trial, the progression of WMH volume was assessed as appearance of new WMH lesions. 8 Please see Tables II through IV in the online-only Data Supplement for additional information on study characteristics, methods used to define SVD, and results of individual trials.
The pooled standardized mean difference of AHM on WMH progression was −0.19 (95% confidence interval, −0.32 to −0.06; I 2 =20%; n=1369; Figure 2A ). Trials with a larger contrast in systolic BP between the treatment groups seemed to have larger effects on WMH progression ( Figure  I in the online-only Data Supplement). The 2 trials reporting on progression of brain atrophy showed conflicting results Figure 2B ).
Discussion
We found that AHM is effective in slowing the progression of WMH. The optimal timing of treatment to prevent WMH progression is unknown. From a prevention perspective, the ideal timing of AHM would probably be early in the course of hypertension. However, WMH seems to progress exponentially and with slow progression rates; in the early stages, it may be difficult to prove effectiveness of AHM within a reasonable time frame. 9 This is less of an issue in later stages because more contrast in WMH volume in comparison with controls may be achieved. A subgroup analysis in one of the included trials indeed showed a stronger effect of AHM in participants with severe WMH at baseline. 8 SVD has been suggested as surrogate outcome in dementia prevention trials. In our meta-analysis, we have shown that AHM can slow the progression of WMH. We did not assess the predictive value of this effect on the prevention of cognitive decline, dementia, or other clinical adverse outcomes. One of the included trials showed that the effect on WMH did not result in a long-term effect on cognition. 7 However, this could have been caused by the diminished effect of the intervention on BP during the observational extension period or selective dropout of cognitively impaired participants. The, as of yet unpublished, SPRINT-MIND (Systolic Blood Pressure Intervention Trial Memory and Cognition in Decreased Hypertension) will provide new information on SVD, cognition, and dementia. 10 As far as we are aware, this is the first systematic review and meta-analysis assessing the effect of AHM on cerebral SVD. A limitation of our review is the small number of trials we could include, prohibiting further secondary analyses. The included trials were heterogeneous in their study populations, level of BP reduction, and methods used to quantify cerebral SVD. We accounted for this heterogeneity by using a random-effects model and standardized outcome measure. We were not able to adjust for potential confounders.
To conclude, AHM can limit the progression of WMH but not of brain atrophy. No evidence is available on the effect of AHM on lacunes, microbleeds, enlarged perivascular spaces, or acute small subcortical infarcts. 
